Raxone is a convenient oral tablet, which is safe and well tolerated.
Raxone is indicated for the treatment of visual impairment in adolescent and adult patients with LHON.1
The European Commission granted marketing authorization for Raxone as the first approved medicine available in all 28 member states of the European Union, Norway, Iceland and Liechtenstein for the treatment of visual impairment in adolescent and adult patients with LHON.
Please click here to access the Raxone SmPC for further information.
Dosing and administration1
Raxone is available as film-coated tablets containing 150 mg idebenone.
The recommended dose is 900 mg/day (two 150 mg tablets, three times a day).
Treatment should be initiated and supervised by a physician with experience in LHON.
Raxone should be swallowed whole with water.
The tablets should not be broken or chewed.
Raxone should be administered with food because food increases the bioavailability of idebenone.
The Raxone SmPC contains guidance on the following special populations (please see section 4.2 of the Raxone SmPC):
Patients with hepatic or renal impairment
For details of special warnings and precautions for use, interactions with other medicinal products and other forms of interactions, guidance on fertility, pregnancy and lactation and effects on ability to drive and use machines, please refer to sections 4.3–4.7 of the Raxone SmPC.
Raxone SmPC, September 2015. Available here. Accessed December 2015